Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Non-muscle-invasive bladder cancer

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

- PMLiVE

FDA panel backs Perjeta in early breast cancer

Unanimous recommendation for use alongside Herceptin

- PMLiVE

AZ licenses Merck ovarian cancer drug

Pays $50m upfront for MK-1775

- PMLiVE

J&J hit by more recalls

Withdraws 200,000 bottles of cough drops in US

- PMLiVE

Celgene wins US pancreatic cancer indication for Abraxane

Adds to breast cancer and lung cancer indications

- PMLiVE

Otsuka to buy cancer biopharma Astex

Takes control of company behind Dacogen in $886m deal

- PMLiVE

J&J files rare blood disorder drug siltuximab in US and EU

Orphan drug to be assessed for use in the treatment of multicentric Castleman disease

- PMLiVE

AZ’s olaparib enters phase III for ovarian cancer

Development of the drug had previously been halted in 2011

- PMLiVE

GSK melanoma therapy Tafinlar cleared in EU

Follows approvals for skin cancer drug in US, Canada and Australia

Roche - Basel

Roche wins EU approval for injectable Herceptin

Can reduce cancer drug's administration time from 90 minutes to two minutes

Bayer symbol

EU nod for Bayer’s Stivarga as Nexavar gets US priority review

Advances pharma company’s ambitions in cancer

- PMLiVE

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links